Home/Pipeline/ODM-208

ODM-208

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 2Active

Key Facts

Indication

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase

Phase 2

Status

Active

Company

Orion Corporation

About Orion Corporation

Orion Corporation is a century-old, publicly traded Finnish pharmaceutical leader with a dual-pillar strategy: developing proprietary drugs in CNS, oncology, and respiratory diseases, and operating a leading contract manufacturing (Fermion CDMO) business. Its major achievement is the global success of Nubeqa® (darolutamide) for prostate cancer, developed with Bayer, which anchors its growing oncology franchise. The company's vertically integrated operations, substantial pipeline, and resilient revenue model position it for sustainable growth in specialty pharma and the CDMO sector.

View full company profile

Therapeutic Areas

Oncology Central Nervous System (CNS) disorders Respiratory diseases Pain Women's Health

Other Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drugs

Drug	Company	Phase	Status
Tomivosertib	eFFECTOR Therapeutics	Phase 2	Terminated
AB001 (²¹²Pb-NG001)	ARTBIO	Phase 1/2	Active - First patient dosed in ARTISAN trial (Jan 2026)
AB-3028	Arsenal Biosciences	IND-Enabling	Active
PRO CAR-201A	PromiCell	Phase 1	Active
PRO CAR-202	PromiCell	Preclinical	Active
FG-3246	Kyntra Bio	Phase 2	Active
PROVENGE (sipuleucel-T)	Dendreon	Approved	Active
RP12146	Rhizen Pharmaceuticals	Phase 1b	Active
Monoclonal Antibody (undisclosed)	MetaCurUm Biotech	Preclinical	Active
ModraDoc006/r	Modra Pharmaceuticals	Phase 2b	Active
SYNC-T	Syncromune	Phase 2	Active
Gedatolisib	Celcuity	Phase 3 Planned	Active